Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.
HC Wainwright Initiates Coverage on Agile Therapeutics, Inc. (AGRX)
Get Analysts' Upgrades and Downgrades Daily
Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.
A number of other analysts have also recently commented on AGRX. Royal Bank Of Canada set a $8.00 price target on shares of Agile Therapeutics and gave the company a “buy” rating in a research report on Sunday, July 16th. ValuEngine raised shares of Agile Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 8th. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a research report on Wednesday, June 14th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $9.00 price objective on shares of Agile Therapeutics in a research report on Monday, May 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $9.93.
Shares of Agile Therapeutics (AGRX) opened at 5.37 on Wednesday. The firm has a 50 day moving average price of $3.90 and a 200 day moving average price of $3.09. The firm’s market cap is $154.69 million. Agile Therapeutics has a 1-year low of $1.82 and a 1-year high of $8.15.
COPYRIGHT VIOLATION NOTICE: “[[title]]” was originally published by [[site]] and is the sole property of of [[site]]. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at [[permalink]].
In related news, Chairman Alfred Altomari acquired 10,000 shares of the business’s stock in a transaction dated Thursday, May 11th. The shares were bought at an average price of $3.51 per share, with a total value of $35,100.00. Following the transaction, the chairman now directly owns 151,587 shares of the company’s stock, valued at $532,070.37. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Renee Selman acquired 53,333 shares of the business’s stock in a transaction dated Thursday, May 11th. The shares were bought at an average cost of $3.68 per share, for a total transaction of $196,265.44. Following the transaction, the insider now directly owns 53,333 shares in the company, valued at $196,265.44. The disclosure for this purchase can be found here. 3.50% of the stock is owned by corporate insiders.
An institutional investor recently raised its position in Agile Therapeutics stock. Renaissance Technologies LLC increased its position in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 209.2% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 64,000 shares of the specialty pharmaceutical company’s stock after buying an additional 43,300 shares during the period. Renaissance Technologies LLC owned approximately 0.22% of Agile Therapeutics worth $365,000 at the end of the most recent quarter. Institutional investors and hedge funds own 79.78% of the company’s stock.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.